Macrocyclic inhibitors of β-secretase: Functional activity in an animal model

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6147-6150

  Stachel, Shawn J ^a   Coburn, Craig A ^a   Sankaranarayanan, Sethu ^a   Price, Eric A ^a   Pietrak, Beth L ^a   Huang, Qian ^a   Lineberger, Janet ^a   Espeseth, Amy S ^a   Jin, Lixia ^b   Ellis, Joan ^b   Holloway, M Katharine ^a   Munshi, Sanjeev ^a   Allison, Timothy ^a   Hazuda, Daria ^a   Simon, Adam J ^a   Graham, Samuel L ^a   Vacca, Joseph P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE; BETA SECRETASE INHIBITOR; MACROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

AMIDES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; MACROCYCLIC COMPOUNDS; MICE; MOLECULAR CONFORMATION; PHTHALIC ACIDS; PROTEASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 33750128392     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060884i     Document Type: Article

References (27)

1. (a) Selkoe, D. J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399A, 23.
2. (b) Goate, A.; Chartier-Harlin, M. C.; Mullan, M.; Brown, J.; Crawford, F.; Findani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Want, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak, V.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of missense mutation in the amyloid presursor protein gene with familial Alzheimer's disease. Nature 1991, 349, 523-527.
3. (c) Hardy, J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. U.S.A. 1997, 349, 704-706.
4. Sinha, S.; Lieberburg, I. Cellular mechanisms of β-amyloid production and secretion. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11049-11053.
5. Beher, D.; Graham, S. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin. Invest. Drugs 2005, 14, 1385-1409.
6. Selkoe, D. J. Amyloid β-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271, 18295-18298.
7. (a) Searfoss, G. H.; Jordan, W. H.; Calligaro, D. O.; Galbreath, E. J.; Schirtzinger, L. M.; Berridge, B. R.; Gao, H.; Higgins, M. A.; May, P. C.; Ryan, T. P. Adipsin: A biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. 2003, 278, 46107-46116.
8. (b) Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadient, R.; Jacobs, R. T.; Zacco, A.; Greenberg, B.; Ciaccio, P. J. Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 2004, 82, 341-358.
9. (a) Cai, H.; Wang, Y.; McCarthy, D.; Wen, H.; Borchelt, D. R.; Price, D. L.; Wong, P. C. BACE1 is the major beta-secretase for generation of A beta peptides by neurons. Nat. Neurosci. 2001, 4, 233-234.
10. (b) Roberds, S. L.; Anderson, J.; Basi, G.; Bienkowski, M. J.; Branstetter, D. G.; Chen, K. S.; Freedman, S.; Frigon, N. L.; Games, D.; Hu, K.; Johnson-Wood, K.; Kappenman, K. E.; Kawabe, T.; Kola, I.; Kuehn, R.; Lee, M.; Liu, W.; Motter, R.; Nichols, N. F.; Power, M.; Robertson, D. W.; Schenk, D.; Schoor, M.; Shopp, G. M.; Shuck, M. E.; Sihna, S.; Svensson, K. A.; Tatsuno, G.; Tintrup, H.; Wijsman, J.; Wright, S.; McConlogue, L. BACE knockout mice are healthy despite lacking the primary β-secretase activity in the brain. Hum. Mol. Genet. 2001, 10, 1317-1324.
11. Thompson, L. A.; Bronson, J. J.; Zusi, F. C. Progress in the discovery of BACE inhibitors. Curr. Pharm. Des. 2005, 11, 3383-3404.
12. (a) Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Jones, K. G.; Loutzenhiser, E. F.; Gregro, A. R.; Rajapakse, H. A.; Lai, M.-T.; Crouthamel, M.-C.; Xu, M.; Tugusheva, K.; Lineberger, J. E.; Pietrak, B. L.; Espeseth, A. S.; Shi, X.-P.; Chem-Dodson, E.; Holloway, M. K.; Munshi, S.; Simon, A. J.; Lawrence, K.; Vacca, J. P. Structure-Based Design of Potent and Selective Cell-Permeable Inhibitors of Human β-Secretase (BACE-1). J. Med. Chem. 2004, 47, 6447-6450.
13. 2NH] reduced amide isosteres Bioorg. Med. Chem. Lett. 2006, 16, 3635-3638.
14. Simon, A. J.; Crouthamel, M. C.; Wu, G.; Price, E. A.; Shi, X. P.; Tugusheva, K.; Stachel, S.; Steele, T.; Coburn, C.; Ellis, J.; Jin, L.; Sankaranarayanan, S. BACE1 inhibition after ICV infusion of a potent, cell-permeable small molecule inhibitor: effects of APP metabolism. Presented at 2005 AD/PD meeting, Sorrento, Italy, 2005.
15. (a) Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem., Int. Ed. 2003, 42, 1356-1360.
16. (b) Hu, X.; Nguyen, K. T.; Verlinde, C. L. M. J.; Hol, W. G. J.; Pei, D. Structure-based design of a macrocyclic inhibitor for peptide deformylase. J. Med. Chem. 2004, 47, 4941-4949.
17. (a) Rojo, I.; Martin, J. A.; Broughton, H.; Timm, D.; Erickson, J.; Yang, H. C.; McCarthy, J. Macrocyclic peptidomimetic inhibitors of β-secretase (BACE): First X-ray structure of a macrocyclic peptidomimetic-BACE complex. Bioorg. Med. Chem. Lett. 2006, 16, 191-195.
18. (b) Hannessian, S.; Yang, G.; Rondeau, J.-M.; Neumann, U.; Betschart, C.; Tintelnot-Blomley, M. Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease b-site amyloid precursor protein cleaving enzyme (BACE) J. Med. Chem. 2006, 49, 4544-4567.
19. The PDB file for BACE-1/inhibitor 1 complex has been deposited with the Protein Data Bank (PDB identifier 2B8L).
20. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Crouthamel, M.-C.; Pietrak, B. L.; Lai, M.-T.; Holloway, M. K.; Munshi, S. K.; Graham, S. L.; Vacca, J. P. Bioorg. Med. Chem. Lett. 2006, 16, 641-644.
21. Brady, S. F.; Singh, S.; Crouthamel, M.; Holloway, M. K.; Coburn, C. A.; Garsky, V. M.; Bogusky, M.; Pennington, M. W.; Vacca, J. P.; Hazuda, D.; Lai, M. Rational design and synthesis of selective BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 601-604.
22. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and activity of a new generation ruthenium-based olefin metahesis catalyst coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org. Lett. 1999, 1, 953-956.
23. Lamb, B. T.; Sisodia, S. S.; Lawler, A. M.; Slunt, H. H.; Kitt, C. A.; Kearns, W. G.; Pearson, P. L.; Price, D. L.; Gearhart, J. D. Nat. Genet. 1993, 5, 22-29.
24. 1-[(7S)-5-methyl-6-oxo-6,7- dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide] Pharmacol. Exp. Ther. 2005, 313, 902-908.
25. Savage, M. J.; Trusko, S. P.; Howland, D. S.; Pinsker, L. R.; Mistretta, S.; Reaume, A. G.; Greenberg, B. D.; Siman, R.; Scott, R. W. Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester J. Neurosci. 1998, 18, 1743-1752.
26. Biological data of a closely related analogue in this class was recently disclosed at the 10th International conference for Alzheimer's disease and related disorders. Sankaranarayanan, S.; Price, E. A.; Wu, G.; Crouthamel, M. C.; Ellis, J. D.; Jin, L.; Stachel, S. J.; Graham, S. L.; Vacca, J. P.; Coburn, C. A.; Simon, A. J. Presented at the 10th International conference for Alzheimer's disease and related disorders, Madrid, Spain, July, 2006; poster #3050.
27. The turnover of Aβ is reported to be approximately 2 h. This is in accord with the rapid recovery when compound levels fall to subefficacious levels.